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INTRODUCTION 
 
 Medicinal Chemistry is a science whose roots lie in all branches of chemistry 
and biology. Pharmaceutical Chemistry is a branch of Science that makes use of the 
general law of chemistry to study drugs (ie) their preparation, chemical nature, 
composition, studies of their physical and chemical proportion, method of quality 
control and the conditions of their usages. 
 The earlier sources of drugs were from plants, animals and mineral sources, 
but due to the lack of potential action and definitive cure and sometime more toxicity, 
the discovery of new drugs that are more potential and less toxic is essential. The 
synthesis of derivatives has been an important part and is aimed at modifying the 
action of drugs, particularly to reduce the side effects and to potentiate the drug 
action. Today more than 60% drugs used in practice are synthesized derivatives and 
day-by-day the scope of synthetic medicinal chemistry is broadening. 
 Once a new pharmaceutical lead compound has been identified, extensive and 
costly effects usually are made to prepare a series of analogue in the hope that even 
better activity will be found. 
 Medicinal chemistry is a highly interdisciplinary science combining organic 
chemistry with biochemistry, computational chemistry, molecular biology, genetic 
engineering, pharmacology, statistics and physical chemistry. Medicinal chemists 
have a chance to participate in the fundamentals of prevention therapy and 
understanding of diseases by providing the drugs either through discovery (or) 
through design. 
It remains a challenging science which provides profound satisfaction to its 
practitioners. 
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QUINAZOLINES – AN OUTLOOK 
 
QUINAZOLINES
2
 
In 1869 Griess prepared the first quinazoline derivative, 2 – cyano 3, 4-
dihydro-4-oxoquinazoline, by the reaction of cyanogens with anthranilic acid. Griess 
apparently recognized the bicylic nature of the product which, he called bicyanoamido 
benzoyl and used this name until 1885. When structure (1) was known with some 
certainly. 
NH
N
CN
O
(1)  
The preparation of the parent quinazoline was discovered after years, later 
when Bischler and Lang obtained it by de-carboxylation of the 2-carboxy derivative. 
A more satisfactory synthesis of quinazoline was subsequently devised by 
Gabriel in 1903 that studied properties and those of its derivatives in greater detail. 
N
N
1
2
3
45
6
7
8
 
 
The name was proposed by Widdege. Other names such as phenmiazine, 
benzyleneamidine, benzo-1,3-diazine,5,6-benzopyrimidine and 1,3-diazanapthaline 
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have occasionally been used. The numbering suggested by Paal and Busch is still in 
use. 
The presence of a fused benzene ring alters the properties of the pyrimidine 
ring considerably. The two nitrogen atoms are not equivalent, and the marked 
polarization of the 3, 4- double bond is reflected in the reactions of quinazoline. The 
properties of substituted quinazolines depend largely on, 
a. The nature of the substitutents. 
b. Whether they are in the pyrimidine ring (or) in the benzene ring  
c. Whether (or) not complete conjugation is present in the pyrimidine ring. 
The chemistry of quinazoline was reviewed by Williamson in 1957, then by 
Lindquist in 1959 and brought up to date by Armarego in 1963. 
 
CHEMICAL PROPERTIES 
Quinazolines is stable in cold dilute acid and alkaline solutions, but it is 
destroyed when these solutions are boiled. When quinazoline is boiled with HCl it 
forms o-aminobenaldehyde, amine and formic acid. 
 
a) Hydrolysis, oxidation and reduction. 
Oxidation of quinazoline in dilute aqueous acid, with two equivalents of 
hydrogen peroxide at room temperature resulted in the formation of a high yield of 3, 
4- dihydro-4-oxo quinazoline. 
In alkaline medium, where the anhydrous neutral species of quinazoline were 
predominantly undergo oxidation with KMnO4 furnished a high yield of 3, 4-dihydro-
4-oxo quinazoline was also formed. 
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Oxidation 
N
N
N
NHOOC
HOOCKMnO4
OH
 
Reduction  
H2ON
N H
+
NH
N
O
 
Catalytic hydrogenation of quinazoline stopped after the absorption of one 
molecules of hydrogen and gave 3,4-dihydro quinazoline. 
Reduction with sodium amalgam gave 1,2,3,4-tetrahydroquinazoline. Lithium 
aluminum hydride and sodium borohydride gave 3,4-dihydro and 1,2,3,4-
tetrahydroquinazoline. 
b) Nucleophilic and electrophilic substitution reactions 
The two known nucleophilic substitution reactions of quinazoline namely with 
sodamide and hydrazine, presumably proceed via the intermediate addition products 
and gave 4-amino and 4-hydrazine quinazoline. 
Nitration is the only known electrophilic substitution reaction of quinazoline. 
Theoretical considerations show that the expected order of reactivity is at positions 8 
> 6 > 5 > 7 > 4 > 2. Quinazoline gives 6-nitroquinazoline with fuming nitric acid in 
concentrated H2SO4. No oxidation of the heterocyclic ring can occur under these 
conditions because the hydrated cation is not present. 
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Conc.HNO3N
N
Conc.H2SO4
N
N
O2N
 
c). Alkylation reactions 
Alkylation of quinazoline takes place on N,3-methyl,3-ethyl-3-alkyl and 3-
benzyl quinazolinium salts readily take up a molecule of alcohol to form the 
corresponding 4-alkoxy-3-alkyl-3,4-dihydro quinazolinium salts. These salts yield the 
pseudo bases, 3-alkyl-3, 4-dihydro-4-hydroxy quinazolines on treatment with strong 
alkali. 
RXN
N
N+
N
R
R'OH
 
N
N
H+
R
OR'
H
+
N
N
R
OH
H
OH-
 
d). Addition reactions 
Quinazoline is very reactive towards anionic reagents which attack position 4. 
Sodium bisulphate, hydrogen cyanide, acetophenone, acetone, 2-butanone and 
cyclohexanone add across the 3,4-double bond of quinazoline. Methyl, ethyl, 
isopropyl, benzyl, t-butyl and phenyl magnesium halides and phenyl lithium also add 
across the 3, 4-double bond to give the corresponding 4-substituted 3, 4-
dihydroquinazolines. 
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SYHTHESIS 
Following methods were reported for the synthesis of oxoquinazolines. 
a) Niementowski’s synthesis 
Niementowski’s found that 3 (or) 4 substituted anthranilic acid when reacted 
with formamide at 125 - 130ºC for 4 hours gave 86% yield of 3, 4-dihydro-4-
oxoquinazoline. 
 
NH
N
O
COOH
NH2
R'CONH2
R' = H (OR) CH3 R'
R
R
 
 
b) Grimmel, Guinther and Morgan’s synthesis. 
3 moles of o-amino benzoic acids, when heated with 3 moles of an amine 
together with one mole of phosphorous trichloride in toluene for two hours, gave high 
yields of 2,3-disubstituted 3,4-dihydro-4-oxoquinazolines. 
N
N
O
COOH
NHCOR
R
R'
3
+ H3PO3+ + +
+
3R'NH2 PCl3
3HCl 3H2O
 
c) From isatoic anhydride 
Isatoic anhydride readily reacts with equimolar quantity of amines to dihydro-
4-oxoquinazolines by refluxing ethyl orthoformate for 1- 6 hours without isolating the 
intermediate amides. 
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O
N
H
O
N
H
NH2
O
RRNH2
N
N
O
RHC(OEt)3
O
 
 
 
d) From1,3,4-Benoxazones (Acylanthranils) and amines. 
1,3,4-Benoxazones react with amines to give 3,4-dihydro-4-oxoquinazolines. 
Primary aliphatic amines and anilines react with 2-methyl-5-nitro-4-oxoquinazolines. 
 
O
N
O
CH3
NO2
N
N
O
CH3
RRNH2
NO2
 
 
e) From ethyl 2-acetamido-5-nitrobenzoate. 
Ethyl 2-acetamido-5-nitrobenzene and alcoholic ammonia when heated in a 
sealed tube at 170ºC, yields 3,4-dihydro –methyl-6-nitro-4-oxoquinazoline. 
COOC2H5
NHCOR NHCOR
N
N
O
Alcoholic
R' - NH2
NHR'
O
R
R'
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f) Sen and Ray’s synthesis 
Boiling a solution of normal (or) isobutyrylanilides with urethane and 
phosphorous pentoxide in the presence of xylene gave 2-propyl and 2-isopropyl-3, 4-
dihydro-4-oxoquinazolines. 
NHCOR'
R NH
N
H
O
O
R
H2NCOOC2H5,P2O5
Xylene, 3 - 5 hrs
 
 
(R = Me, OMe, OEt; R’ = Me, Et, Pr, Iso-Pro, Ph) 
g) From anthranilic acid and ureas. 
      The fusion of anthranilic acid with urea to give 1,2,3,4-tetrahydro-2,4-
dioxoquinazoline was first described by Griess. 
COOH
NH2
R NH
N
H
O
O
R
Urea
 
h) From o-ureidobenzoic acid. 
o-ureidobenzoic acids are readily prepared from the corresponding anthranilic 
acid and potassium cyanate. The ureido acids are then easily cyclised to the respective 
1,2,3,4-tetrahydro-2,4-dioxoquinazolines by heating with acid (or) alkali. Anthranilic 
esters and amides as well as undergo this reaction. 
COR'
NH2
COR'
NHCONH2
NH
N
H
O
O
KNCOR
R
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i) From o-ethoxy carbonylaminobenzoic esters (or) amides. 
When o-ethoxy carbonylamino benzamide and its 4-methyl derivatives are 
heated above their melting points, they lose water and from 1,2,3,4-tetrahydro-2,4-
dioxoquinazoline. 
COOR
NH2
COOR
NHCOOEt
ClCOOEt RNH2
CONHR
NHCOOEt
NR
N
H
O
O
-EtOH
 
 
j) From phthalic acid derivatives. 
The use of derivatives of phthalic acid for the preparation of dioxoquinazoline 
necessitates rearrangement of the Hoffmann cruties (or) Lossan type. Reaction of 
phthalamide (or) phthalimide, N-methyl and N-ethyl phthalimide with alkali 
hypobromite gives the 1,2,3,4-tetrehydro 2,4-dioxoquinazoline. 
 
N
O
O
R
NR
N
H
O
O
NaOBr
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k) From Isatins 
α-isatin oxime rearranges to 1,2,3,4-tetrahydro-2,4-dioxoquinazoline on 
heating with dilute sodium hydroxide, β-imino derivatives of isatin, on the other hand, 
require oxidation with hydrogen peroxide in alkaline solution in order to from the 
dioxoquinazoline. 
 
O
N
H
O
N
H
NR
O
NR
N
H
O
O
H2O2
OH
NR
 
 
Quinazoline is an aromatic benzopyrimidine ring system. It was earlier known 
as benzo 1,3-diazine, first prepared by Gabriel, in 1903. 
N
N
Quinazoline  
It was isomeric with the compounds, cinnoline and quinoxaline of the many 
derivatives of quinazoline system known so far, keto quinazolines also called as 
quinazolinones are the most important compounds. 
 
 Depending upon the position of the Keto (or) Oxo group, these compounds 
may be classified into two types, 
1. 2-(1H) Quinazolinone 
2. 4-(3H) Quinazolinone 
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N
H
N
O
Quinazolin -2(1H)-one   
N
NH
O
Quinazolin -4(3H)-one 
The structure activity relationship studies of Quinazolinone ring system 
revealed in various literature suggests position 2,6,8 are very much important for 
structure activity studies and position 3 should be attached to different heterocyclic 
rings for better chemotherapeutic activity. 
 
From the reviews of various literatures, it was known that Quinazolin-4-ones 
have emerged as an important class of nitrogenated heterocycles that have attracted 
significance synthetic interest because of their therapeutic and pharmacological 
properties such as Antibacterial, Antifungal, Anthelmintic, Anti-inflammatory, 
Anticonvulsant, CNS depressant, Hypoglycemic, Antiparkinsonian, Anticancer, 
Antiviral, Antihistaminic, Antihypertensive, Analgesic and many other activities. 
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Literature Review 
 
1. P. Mani Chandrika et al, synthesized novel 2,4,6-tri- Substituted Quinazoline 
derivatives Antibacterial and cytotoxic agents. 
N
N
X
Cl
R
X = H
R = C6H5, CH3, CF3, I, Br 
2. L. Cipak et al, synthesized 2-phenoxy methyl 3-H-Quinazolin-4-one as Anticancer 
agents. 
N
NH
O
C
H2
O
 
 
3. R.K. Kawadkar, B.J. Ghiya reported on synthetis of new Quinazolin-4-one 
compounds of medicinal importance. 
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N
N
R
R1
O
R = CH3. C6H5
R1 = H, C
NH
NH2
H
N C
S
H
N,
 
4. V. Murugan et al, reported on the synthesis of 2-substituted Quinazolin-4(3H)-
ones as a new class of Anticancer agents. 
N
N
O
Br
Br
CONHNH
Ar
Ar = -C6H5, -CH=CH-C6H5, -M-C6H5-NO2  
5. N.B. Patel and J.D. Lilakar reported on the synthesis and Antibacterial activity of 
new substituted 4-(3H)-Quinazolinones. 
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N
N
O
CH2
H
N
Cl
Cl
R
R = H, 2-NO2, 2-CH3, 2-OOH3, 2-Cl, 3-NO2, 3-CH3, 3-OCH3, 3-Cl 
6. P.C. Sarkar et al, reported on the synthesis and biological evaluation of some new 
2-aryl/substituted aryl 6,8-substituted Quinazol-4(3H)-ones. 
N
N
O
X2
X1
R1
N
S
R4
R3
R2
X1 = X2 = R2 = R3 = R4 = H
X1 = X2 = R2 = R3 = R4 = H
X1 = X2 = R2 = R3 = R4 = H
R1 = C6H5-
R1 = P-Cl C6H5-
R1 = M-Cl C6H4-  
7. Tsuyoshi Nagase, Takashi Mizutani et al, synthesis and evaluation of structurally 
constrained Quinazolinone derivatives as potent and selective histamine H3 
receptor inverse agonists. 
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N
N
CF3 O
O N
 
8. Hirohiko Hasegawa, Masami Muraoka et al, discovery of a novel potent Na+/Ca+2 
exchanger inhibitor. Design, synthesis and structure activity relationships of 3,4-
Dihydro-2(1H)-Quinazolinone derivatives. 
N
N
Cl
H
Ph
NMe2
N
N
Cl
O
NMe2
Ph
S
 
9. Jatav Varsha et al, reported on the synthesis and Antimicrobial activity of novel 2-
methyl-3(1,3,4-Thiadiazoyl) 4-(3H) Quinazolinone. 
N
N
CH3
O
N
S
N
CH3
 
10. Perrine JW et al, reported on the Anti-inflammatory and other pharmacodynamic 
properties of five members of the 4-aryl-1-isopropyl-2(1H)-Quinazolinones. 
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N
N
O
OH
HC
CH3
CH3  
11. Lyman R. Caswell et al, reported on the synthesis of 2-aryl-4(3H)-Quinazolinone-
5-carboxylic acids. 
NHN
C
OH
O
O
OCH3
 
12. Mazaahir Kidwai et al, reported on the novel route to the Neimentowski reaction 
for Quinazolinone synthesis. 
N
N
O
R
R = 3-Chloro, 4-Fluorophenyl, 2-fufuryl, 2-pyridyl 
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13. I. Philipova et al, reported on the synthesis of some 2-Substituted 4-(3H)-
Quinazolinone derivatives. 
N
NH
O
R
R = aromatic aldehydes  
14. N.A. Gangwal et al, reported on the synthesis and QSAR studies of substituted 
4(1H)-Quinazolinones. 
N
H
NH
O
 
15. A.R. Bhat et al, reported on synthesis and biological activities of Mannich bases 
of 7-nitro 2-methyl 4(3H)-Quinazolinones. 
N
N
CH3
O
H2
C
O2N
NH
N
S
N
Ar
 
 
16. Ram Lakhan and Rakesh K. Banerjee et al, reported on a simple preparation of 2-
thioxo-4(3H) Quinazolinones. 
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N
H
N
S
O
R
O2N
 
17. M.A. Aziza et al, reported on the synthesis and Antimicrobial activities of 
somenew 3-heteroaryl Quinazolin 4-ones. 
N
N
CH3
O
H2
C N
 
18. Krishna Srivastava et al, reported on the synthesis of thiazolyl Quinazolines for 
studying their Antiviral activity against Japanese encephalitis virus, a RNA virus 
of high pathogenicity. 
N
N
O
N
S
Ph
R
N
N
Ph
O
N
S
R
R = Different aromatic aldehydes
 
19. Deepti Kohli et al, reported on the synthesis and Antibacterial activity of 
Quinazoline derivatives. 
                                                                                                                     Chapter-1  
Dept. of Pharmaceutical chemistry, Madurai Medical College  Page 19 
 
N
N
O
H
N C
O
H2
C O
R
R = Substituted Phenols  
20. YA Ammar, YA Mohamed et al, reported on the synthesis of some biologically 
active 4(3H) Quinazolinones derived from 2,3-pyridine dicarboxylic anhydride. 
 
21. Pankaj S. Salunkhe et al, reported on the study of analgesic and Anti-
inflammatory evaluation of some 2,3-Dihydro Quinazoline 4-one derivatives. 
N
H
N
OH
O
N
C6H5
C
H
R
R = Different aldehydes  
22. Mosaad S. Mohamed and Mohsen M. Kamel et al, reported on the synthesis, 
biological evaluation, and Molecular docking of Quinazoline-4(1H)-one 
derivatives as Anti-inflammatory and analgesic agents. 
 
 
23. B. Kiruthiga, K. Ilango et al, reported on the synthesis of some new 2-substituted 
Quinazolin-4-one derivatives and their biological activities. 
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N
N
O
CH2CH2 N
H
Ar
COOH
Ar = Aromatic Amines  
24. Dhansay Dewangan and D.K. Tripathi et al, reported on the synthesis, 
characterization and Anti-inflammatory Analgesic and Antimicrobial activities of 
substituted 4-(4-oxo-2-phenyl Quinazolin-3(4H)-yl) N-aryl-methylene benzene 
sulfonamide derivatives. 
N
N
O
S
O
O
N
R
R = Aromatic aldehydes  
25. K. Hemalatha and K. Girija et al, reported on the synthesis of some novel 2,3- 
disubstituted Quinazolinone derivatives as analgesic and Anti-inflammatory 
agents. 
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N
N
R
O
R1
X2
X1
X1, X2 = H, Br
R = -CH3, -C6H5
R1 = -C6H4CH3, -NHCOC6H4N 
26. Ponnilavarasan Ilangovan and Swastika Ganguly et al, reported on the design and 
synthesis of novel Quinazolinone derivatives as broad spectrum Anticonvulsant 
and Antimicrobial agent. 
N
N
R
O
H
N C
O
C
H
N N
R2
R1
R = Phenyl
R1 = H
R2 = 2-OH-Phenyl, 4-OH-Phenyl
R1 = R2 = Furan,Isatin, Phenyl  
27. Jayshari S. Pattan et al, reported on the synthesis and evaluation of some new 
Quinazolone derivatives for their Antimicrobial activity. 
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N
N
O
HN R
N
S
N
R
R = Different Amines  
 
28. Vinod K. Tiwari et al, synthesized 3-heteroaryl-2- thioxo-2,3-dihydro Quinazolin-
4-(1H)-one. 
N
S
N
O
R1
R2
N
X
N
X = O, S
R = H, Cl
R1 = H, CH3
R2 = CH3, H  
29. L. Cipak et al, synthesized 2-phenoxy methyl 3-H Quinazolin-4-one as Anticancer 
agents. 
N
NH
C
H2
O
O
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30. Bernard Pirotte et al, reported on the synthesis and KATP channel activity of 2-
alkyl amino 6-halogeno Quinazolin-4(3H)-ones. 
N
NH
N
O
X
H
R
X = Cl, I
X = Cl, I
X = Cl, I
X = Cl, I
R = CH(CH3)2
R = CH(CH3) CH2CH3
R = CH(CH3) CH(CH3)2
R = CH2C6H11  
31. M.E. Abd El-Fattah reported on the synthesis of 4-substituted 2-phenyl amino 
Quinazolines. 
N
NH
NHPH
OH2C
N
O
NH
S
 
32. B. Shivarama Holla, SHalini Shenoy et al, reported on the synthesis and 
Antibacterial activity of some fluorine containing aryl furyl vinyl Quinazolinones. 
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N
N
C
H
O
C
H
Ar (Arf)
Cl
F
O Ar
Arf =
 
33. S. El-Meligie, AK El-Ansary et al, reported on the synthesis and Antimicrobial 
activity of 2-(2-aryl vinyl)-7-substituted-Quinazolin-4(3H)-ones. 
N
N
C
H
O
C
H
Cl
O C
H2
C C Ar
O O
 
34. Zachary A Knight et al, reported on the pharmacological map of the P13-K family 
defines a role for P110X in insulin signaling. 
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N
N
NH
N
OCH3
H3CO
O N
 
35. Chang Xie et al, synthesized imidazo [2,1-b] Quinazoline-2,5(1H,3H)-diones. 
N
N
N
O
R1
O
R2
R1 = Ph, 4-Chlorophenyl, 3-Methyl phenyl
R2 = H, CH3, C6H5CH2  
 
36. PSN Reddy et al, reported on the synthesis of novel bis Quinazolinonyl-β-lactams. 
N
N
O
CH3
N
O
Z N
NN
O
H3C
O
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37. D.M. Purohit, V.N Patolia reported on the synthesis and Antimicrobial activity of 
2-(1’[4-chlorophenyl)-2’-methyl propyl]-3N- (aryl) Quinazolin-4(3H) ones. 
N
N
O
R
H3C CH3
Cl
R = Aryl  
38. NIzamuddin, Manoj Kr Srivastava reported on the synthesis, Antibacterial, 
Antiviral activity of some 2-methyl-3-(aryl thio-carbamido) Quinazol-4-ones and 
2-methyl-3-cayliden-carboxomido) Quinazol-4-ones. 
N
N
CH3
O
R
R = C NH
O
R1
H
N C
O
H
N
R
N CH
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39. Quinazolinones as Anti-inflammatory agents: m. Jonathan Fray et al, reported on 
the synthesis of substituted 2-amino 4-Quinazolines via ortho fluoro benzoyl 
guanidines as Anti-inflammatory agents. 
 
40. Emilan Geo Gescu, Floretina Georgescu, Mino R. Caira Alina Micolescu, Calin 
Danila, Petru Fillip and Florea Dunutrascu, A new synthesis of pyrrolo (1,2-C) 
Quinazoline from Quinazolinium n-ylides a re-investigation, ARKIVOC (2009), 
232-241. 
 
41. Deepti Kohli, S. Riaz Hashini, S. Vishal, Manish Sharma and Ashutosh Kumar 
Singh, synthesis and Antibacterial activity of Quinazolinone derivatives, 
International Journal of Pharmacy and Pharmaceutical Sciences, (2009), 1, 163-
169. 
 
42. Juhhui You, Changwen Ye, Yabriao Weng, Xihao Mo and Yuliang Wang, 
synthesis and Anticoccidial activity of 4-(2-methoxy phenyl)-2-oxobutyl 
Quinazoline derivatives, ARKIVOC (2008), (XVII) 1-11. 
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Chapter II 
Objective of present work 
Quinazolin-4-(3H)-one is a versatile lead molecule for the design of potential 
bio-active agents. 
N
NH
O
Quinazolin -4(3H)-one 
From the literature review, it was known that most of the Quinazolin-4(3H)-
ones having substitution at C-2 and N-3 positions possess various interesting 
pharmacological activities. 
In the present work, Novel 2-phenyl-3-amino (substituted) quinazolin-4(3H)-
ones were synthesized and their Anticancer and Anti-inflammatory activities were 
evaluated. 
 
The objective of the present work can be summarized as follows: 
 
I) Synthesis: 
To synthesize 2-phenyl-3-substituted amino quinazolin-4(3H)-one derivatives 
by the following steps 
• First Step is the cyclization of Anthranilic acid with benzoyl chloride to give 
2-phenyl-4H-3,1-benzoxazine-4-one by Schotten-Bauman reaction. 
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N
O
O
2-Phenyl-4H-3,1-benzoxazin-4-one  
• Second step is the condensation of 2-phenyl-4H-3,1-benzoxazine-4-one with 
hydrazine hydrate to yield 3-amino-2-phenyl quinazolin-4(3H)-one. 
 
N
N
O
NH2
3-Amino-2-phenyl quinazolin -4-(3H)-one 
• Third step is the substitution of various amines to yield 3-substituted amino-2-
phenyl- quinazolin-4(3H)-one. 
N
N
O
HN
H2
C R
 
 
II) Characterization: 
 Characterization of the synthesized compounds by the analytical techniques 
like melting point, Thin layer chromatography, Infrared spectral analysis, Nuclear 
magnetic resonance spectral analysis, mass spectral analysis methods. 
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III) Pharmacological screening 
• Screening of the synthesized compounds for Anticancer activity using 
Dalton’s lymphoma ascities cells in Swiss albino mice. 
• Screening of the synthesized compounds for Anti-inflammatory activity using 
the carrageenan rat paw edema model. 
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Scheme of reaction 
NH2
OH
O
+ C Cl
O
Anthranilic acid Benzoyl Chloride
Pyridine
N
O
O
2-Phenyl-3,4-dihydro benzoxazin-4-one
NH2 - NH2 . H2O
Ethanol
N
N
O
NH2
3-amino-2-phenyl quinazolin-4(3H)-one  
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S1 
N
N
O
HN CH2 N
2-phenyl-3{[(dicyclohenyl amino) methyl] amino}- quinazolin-4(3H)-one 
S2 
N
N
O
HN CH2
N
2-phenyl-3{[(1H-indol-1-yl methyl) amino]}- quinazolin-4(3H)-one 
 
S3 
N
N
O
HN CH2 N NH
2-phenyl-3{[(piperazinyl) N-methyl] amino}- quinazolin-4(3H)-one 
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S4 
N
N
O
HN CH2
H
N OH
3{[(4-hydroxy phenyl) amino] methyl}amino -2-phenyl quinazolin-4(3H)-one 
 
S5 
N
N
O
HN CH2
H
N
2-phenyl-3{[(phenyl amino) methyl]amino}-quinazolin-4(3H)-one 
 
 
S6 
N
N
O
HN CH2
H
N
4-{[(2-phenyl 4-oxoquinazolin-3(4)-4-yl) amino] methyl}amino benzoic acid
COOH
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S7 
N
N
O
HN CH2
3-{[(1H-benzimidazol -1-yl-methyl) amino] 2-phenyl}quinazolin-4(3H)-one
N
N
 
 
S8 
N
N
O
HN CH2
4-{[(2-pheyl-4-oxoquinazolin-3(4H)-yl) amino] methyl amino} benzene sulphonanmide
H
N SO2NH2
 
 
S9 
N
N
O
HN CH2
2-phenyl -3-{[(diethanol amino) methyl] amino}quinazolin-4(3H)-one
CH2CH2OH
CH2CH2OH
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S10 
N
N
O
HN CH2
2-phenyl -3-{[(morpholinyl)N-methyl] amino}quinazolin-4(3H)-one
N O
 
 
 
 
 
  
 
  
 
Chapter-III 
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Chapter III 
Experimental Work 
Synthesis 
Step: I 
Synthesis of 2-phenyl-3H-quinazolin-4-one 
Chemicals required: 
 Anthranilic acid 
 Benzoyl chloride 
 Pyridine 
 Ethanol 
Procedure: 
 Anthranilic acid (1 mol) was treated with Benzoyl chloride (1 mol) in presence 
of pyridine and stirred for 3 hours and the resulting mixture was treated with 5% 
NaHCO3 solution to get 2-phenyl benzoxazine 4-one and the precipitate was filtered 
and recrystallized from ethanol. 
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Synthesis of 2-phenyl-3H-quinazolin-4-one 
Step: I 
NH2
OH
O
+ C Cl
O
Anthranilic acid Benzoyl Chloride
Pyridine
N
O
O
2-Phenyl-3,4-dihydro benzoxazin-4-one
Reflux for 3 hours
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Synthesis: 
Step II: 
Synthesis of 3-amino-2-phenyl-3H-quinazolin-4-one 
Chemicals required: 
 Pyridine 
 Hydrazine hydrate 
 Ethanol 
Procedure: 
 The solid obtained (1 mol) was treated with hydrazine hydrate (2 mol) in 
presence of ethanol and refluxed for 2-3 hours to form 2-phenyl 3-amino quinazolin-
4-one. The content was cooled and the solid separated was filtered, washed well with 
water, dried and recrystallised from ethanol. 
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Synthesis of 3-amino-2-phenyl-3H-quinazolin-4-one 
Step: II 
N
O
O
+ NH2 - NH2 . H2O
2-phenyl-3H-quinazolin-4one
Hydrazine hydrate
Pyridine
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one  
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Synthesis 
Step III 
Synthesis of 3-substituted-2-phenyl-3H-quinazolin-4-one by Mannich reactions 
Chemicals required: 
3-amino-2-phenyl-3H-quinazolin-4-one - 0.01 mol 
Formaldehyde - 0.15 mol 
Amines - 0.01 mol 
Ethanol - 20 ml  
Procedure: 
 A mixture of 3-amino 2-phenyl-quinazolin-4(3H)-one (0.01 mol), amines (like 
Dicyclo hexylamine, Indole, piperazine, 4-aminophenol, aniline, PABA, 
Benzimidazole, Sulphanilamide, diethanolamine, morpholine (0.01 mol) and 
formaldehyde (0.15 mol) was taken in 20 ml of ethanol and heated under reflux for 4-
5 hours. After coming to room temperature, the mixture was poured into crushed ice. 
Mannich base thus separated was filtered and recrystallized from ethanol. The purity 
of the compound was further confirmed on TLC using methanol : Chloroform : water 
(9:1:1) Iodine vapour was used for the detection of spots. 
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Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO + R' H
Formaldehyde Amine containing compunds
Ethanol / reflux for 4 hours
N
N
O
NH
H2
C R
2-phenyl-3{[(amino substituted) methyl] amino}-quinazolin -4(3H)-one  
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I Synthesis of 2-phenyl-3{[(dicyclohexylamino) methyl] amino}-quinazolin -
4(3H)-one. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
Dicyclohexyl amine - 0.01 mol 
Ethanol  - 20 ml 
 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
N
N
O
NH CH2
2-phenyl-3{[(dicyclohenyl amino) methyl] amino}-quinazolin -4(3H)-one
HN
Dicyclohenyl amine
N
 
                                                                                                                   Chapter III                              
Dept. of Pharmaceutical chemistry, Madurai Medical College  Page 43 
 
II Synthesis of 2-phenyl-3{[(1H-indol-1-yl methyl) amino]}-quinazolin -4(3H)-
one. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
Indole   - 0.01 mol 
Ethanol  - 20 ml 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
Indole
N
H
N
N
O
HN CH2
N
2-phenyl-3{[(1H-indol-1-yl methyl) amino]}- quinazolin-4(3H)-one  
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III Synthesis of 2-phenyl-3{[(Piperazinyl) N-methyl] amino}-quinazolin -4(3H)-
one. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
Piperazine  - 0.01 mol 
Ethanol  - 20 ml 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
Piperazine
HN NH
N
N
O
HN CH2 N NH
2-phenyl-3{[(piperazinyl) N-methyl] amino}- quinazolin-4(3H)-one  
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IV Synthesis of 3-{[(4-hydroxy phenyl) amino] methyl} amino-2-phemyl 
quinazolin-4(3H)-one. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
4-aminophenol - 0.01 mol 
Ethanol  - 20 ml 
 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
4-amino phenol
H2N OH
N
N
O
HN CH2
H
N OH
3{[(4-hydroxy phenyl) amino] methyl}amino -2-phenyl quinazolin-4(3H)-one  
                                                                                                                   Chapter III                              
Dept. of Pharmaceutical chemistry, Madurai Medical College  Page 46 
 
V Synthesis of 2-phenyl-3{[(phenyl amino) methyl] amino}-quinazolin -4(3H)-
one. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
Aniline  - 0.01 mol 
Ethanol  - 20 ml 
 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
Aniline
NH2
N
N
O
HN CH2
H
N
2-phenyl-3{[(phenyl amino) methyl]amino}-quinazolin-4(3H)-one  
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VI Synthesis of 4-{[(2-phenyl-4-oxoquinazolin-3(4H)-yl) amino] methyl} amino 
benzoic acid. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
P-amino benzoic acid - 0.01 mol 
Ethanol  - 20 ml 
 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
P-amino benzoic acid
H2N COOH
N
N
O
HN CH2
H
N
4-{[(2-phenyl 4-oxoquinazolin-3(4)-4-yl) amino] methyl}amino benzoic acid
COOH
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VII Synthesis of 3-{[(1H-benzimidazol-1-yl methyl) amino]}-2-phenyl-quinazolin 
-4(3H)-one. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
Benzimidazole - 0.01 mol 
Ethanol  - 20 ml 
 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
Benzimidazole
N
H
N
N
N
O
HN CH2
3-{[(1H-benzimidazol -1-yl-methyl) amino] 2-phenyl}quinazolin-4(3H)-one
N
N
 
                                                                                                                   Chapter III                              
Dept. of Pharmaceutical chemistry, Madurai Medical College  Page 49 
 
VIII Synthesis of 4-{[(2-phenyl-4-oxoquinazolin-3(4H)-yl) amino] methyl} amino 
benzene sulphonamide. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
Sulphanilamide - 0.01 mol 
Ethanol  - 20 ml 
 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
Sulphanilamide
H2N SO2NH2
N
N
O
HN CH2
4-{[(2-pheyl-4-oxoquinazolin-3(4H)-yl) amino] methyl amino} benzene sulphonanmide
H
N SO2NH2
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IX Synthesis of 2-phenyl-3{[(diethanol amino) methyl] amino}-quinazolin -4(3H)-
one. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
Diethanolamine - 0.01 mol 
Ethanol  - 20 ml 
 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
Diethanolamine
HN
CH2CH2OH
CH2CH2OH
N
N
O
HN CH2
2-phenyl -3-{[(diethanol amino) methyl] amino}quinazolin-4(3H)-one
CH2CH2OH
CH2CH2OH
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X Synthesis of 2-phenyl-3{[(Morpholinyl) N-methyl] amino]}-quinazolin -4(3H)-
one. 
Chemicals required: 
3-amino-2-phenyl quinazolin-4(3H)-one - 0.01 mol 
Formaldehyde  - 0.15 mol 
Morpholine  - 0.01 mol 
Ethanol  - 20 ml 
Reactions: 
N
N
O
NH2
3-amino-2-phenyl-3H-quinazolin-4-one
+ HCHO +
Formaldehyde
Ethanol / reflux for 4 hours
Morpholine
HN O
N
N
O
HN CH2
2-phenyl -3-{[(morpholinyl)N-methyl] amino}quinazolin-4(3H)-one
N O
 
 
  
 
Chapter-IV 
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Chapter IV 
Table No. 1-Physical data of titled compounds 
Code Chemical name M.F M.Wt.  yield Appearance 
S1 2-phenyl-
3{[(dicyclohexylamino) 
methyl] amino}-quinazolin -
4(3H)-one 
C27H34N4O 430 91.55% Black gummy 
solid 
 
S2 2-phenyl-3{[(1H-indol-1-yl 
methyl) amino]}-quinazolin 
-4(3H)-one. 
C23H18N4O 366 78.37% Black coloured 
Solid 
S3 2-phenyl-3{[(Piperazinyl) N-
methyl] amino}-quinazolin -
4(3H)-one 
C19H21N2O 335 89.33% Pale yellow 
coloured  Solid 
S4 3-{[(4-hydroxy phenyl) 
amino] methyl} amino-2-
phemyl quinazolin-4(3H)-
one 
C21H18N4O2 358 81.22% Brown 
coloured 
crystals 
S5 2-phenyl-3{[(phenyl amino) 
methyl] amino}-quinazolin -
4(3H)-one 
C21H18N4O 342 75.65% Yellowish 
crystals 
S6 4-{[(2-phenyl-4-
oxoquinazolin-3(4H)-yl) 
amino] methyl} amino 
benzoic acid 
C22H18N4O3 386 83.37% Pale brown 
coloured Solid 
S7 3-{[(1H-benzimidazol-1-yl 
methyl) amino]}-2-phenyl-
quinazolin -4(3H)-one 
C22H17N5O 367 90.05% Black coloured 
Solid 
S8 4-{[(2-phenyl-4- C21H19N5O3S 421 78.84% Pale yellow 
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oxoquinazolin-3(4H)-yl) 
amino] methyl} amino 
benzene sulphonamide 
coloured Solid 
S9 2-phenyl-3{[(diethanol 
amino) methyl] amino}-
quinazolin -4(3H)-one 
C19H22N4O3 354 85.39% Black coloured 
crystals  
S10 2-phenyl-3{[(Morpholinyl) 
N-methyl] amino]}-
quinazolin -4(3H)-one. 
C19H20N4O2 336 91.03% Black coloured 
Solid 
 
Melting point analysis: 
Melting point was found in an open end capillary tube method by electrically 
heating melting point apparatus. 
 
The melting point synthesized compounds. 
Table No.2 
S. No. Compound Code Melting point (°C) 
1 S1 156 
2 S2 137 
3 S3 168 
4 S4 159 
5 S5 148 
6 S6 125 
7 S7 124 
8 S8 149 
9 S9 135 
10 S10 141 
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Table: No .3 
                     Elemental Composition Analysis ( %) 
Code C H N O S 
S1 75.31 7.96 13.01 3.72 - 
S2 75.39 4.95 15.29 4.37 - 
S3 68.04 6.31 20.88 4.77 - 
S4 70.38 5.06 15.63 8.93 - 
S5 73.67 5.3 16.36 4.67 - 
S6 68.38 4.7 14.5 12.42   
S7 71.92 4.66 19.06 4.35 - 
S8 59.84 4.54 16.62 11.39 7.61 
S9 64.39 6.26 15.81 13.54 - 
S10 67.84 5.99 16.66 9.51  - 
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Thin Layer Chromatography Analysis 
 Thin layer chromatography analysis was carried out by using silica gel G (0.5 
mm thickness) coated over glass plate (12 x 20 cm) as stationary phase, Methanol : 
Chloroform : Water (9:1:1) as mobile phase, the spots were visualized by iodine 
vapours.  
Rf value of the synthesized compounds 
Table No.4 
S. No. Compound Code Rf Value 
1 S1 0.9305 
2 S2 0.8667 
3 S3 0.9054 
4 S4 0.8714 
5 S5 0.9577 
6 S6 0.8933 
7 S7 0.8472 
8 S8 0.9459 
9 S9 0.8875 
10 S10 0.9206 
 
 
  
 
  
 
Chapter-V 
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Chapter V 
Infrared Spectral Analysis 
 The structure of the synthesized compounds was elucidated by PERKIN-
ELMER FT-IR spectrophotometry using Potassium bromide disc. The Infrared values 
were measured as wave number in cm
-1
 and the results are shown below. 
Compound S1 
IR Values 
3412        (NH, 2
0
 amine) 
2932        (CH str. aromatic) 
2858         (CH str. alkyl) 
1654         (C=O str. of quinazoline) 
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Compound S2 
IR Values 
3238        (NH, 2
0
 amine) 
3053      (CH str. aromatic) 
2972         (CH str. alkyl) 
1658         (C=O str. of quinazoline) 
1585, 1456   (C-N str.) 
742           (CH bending, 4-substituted benzene) 
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Compound S3 
IR Values 
3404        (NH, 2
0
 amine) 
3061        (CH str. aromatic) 
1654         (C=O str. of quinazoline) 
1583        (C-N str.) 
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Compound S4 
IR Values 
3429        (OH str., phenolic) 
2935        (CH str. aromatic) 
1653         (C=O str. of quinazoline) 
1510        (C-N str.) 
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Compound S5 
IR Values 
3323                 (NH, 2
0
 amine) 
2921                 (CH str. aromatic) 
1693                 (C=O str. of quinazoline) 
1571, 1477        (C-N str.) 
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Compound S6 
IR Values 
3344                  (NH, 2
0
 amine) 
2977                   (CH str. alkyl) 
1701                  (C=O str. carboxylic acid) 
1674                  (C=O str. of quinazoline) 
1230                  (C-O str.) 
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Compound S7 
IR Values 
3325                  (NH, 2
0
 amine) 
3032                  (CH str. aromatic) 
1670                  (C=O str. of quinazoline) 
1562. 1450        (C-N str.) 
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Compound S8 
IR Values 
3305.69  N-H stretch (in SO2 NH2) 
1660.23  C=O stretch 
901.11  S-N stretch 
1370.56  SO2 stretch 
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Compound S9 
IR Values 
2923        (CH str. aromatic) 
1020        (C-O str.primary alcohol) 
1649         (C=O str. of quinazoline) 
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Compound S10 
IR Values 
3348                 (NH, 2
0
 amine) 
3060                 (CH str. aromatic) 
2920                  (CH str. alkyl) 
1683                 (C=O str. of quinazoline) 
1566, 1440        (C-N str.) 
1099                  (C=O str)  
 1293                 (C-O str.) 
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Nuclear Magnetic Resonance spectral analysis 
 The structure of the synthesized compounds were elucidated by BRUCKER 
300 Mhz FT-NMR using TMS (Tetra Methyl Silane) as an internal standard. The 
proton magnetic resonance spectroscopic values are measured in δppm in CDCl3. 
Compound S1 
NMR Values 
1.38-1.49  (m, 16H, CH2 of cyclo hexane) 
2.57            (s, 2H, -CH of cyclo hexane) 
3.75            (s, 2H,  -CH2 of amino alkyl) 
7.62-7.9     (m, 9H, ArH) 
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Compound S2 
NMR Values 
7.142-8.154       (m, 13H, ArH) 
6.998                  (s, 1H, CH2 of (3) indole) 
7.016                  (s, 1H, CH2 of (2) indole) 
4.668                  (s, 1H, -NH) 
3.595                  (s, 2H, CH2) 
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Compound S3 
NMR Values 
7.195-8.150      (m, 9H, ArH) 
4.401                 (s, 1H, -NH) 
3.584                 (s, 2H, -CH2) 
2.254                 (s, 2H, CH2 of (3) piperazine) 
2.157                 (s, 2H CH2 of (2) piperazine) 
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Compound S4 
NMR Values 
7.034- 8.280    (m, 14H, ArH) 
5. 230                 (s, 1H, -OH) 
4.498                 (s, 1H, -N-NH) 
3.855                 (s, 2H, -CH2) 
3.175                 (s, 1H, -NH Ph) 
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Compound S5 
NMR Values 
6.990-7.923      (m, 14H, ArH) 
4.207                 (s, 1H, -N-NH) 
3.708                 (s, 1H, -NH Ph) 
3.058                 (s, 2H, -CH2) 
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Compound S6 
NMR Values 
9.945                 (s, 1H, -COOH) 
6.961-8.147      (m, 13H, ArH) 
4.721                 (s, 1H, -N-NH) 
3.328                 (s, 1H, -NH Ph) 
3.970                 (s, 2H, -CH2) 
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Compound S7 
NMR Values 
8.834              (s, 1H, -CH of benzimidazole) 
7.188-8.163   (m, 13H, ArH) 
4.697             (s, 1H, -NH) 
3.719             (s, 2H, -CH2) 
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Compound S8 
NMR Values 
2.597                 (s, 2H, CH2) 
3.395                 (s, 1H, NH-Ph) 
4.779                 (s, 1H, -N-NH) 
5.512                 (s, 2H, SO2NH2) 
7.245-8.846       (m, 13H, ArH) 
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Compound S9 
NMR Values 
6.955-7.527      (m, 9H, ArH) 
4.821                 (s, 1H, -OH) 
3.785                 (s, 1H, -NH) 
3.482                 (s, 2H, -CH2) 
2.616-2.557       (t, 2H, N-CH2) 
4.241-4.179       (t, 2H, CH2-OH) 
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Compound S10 
NMR Values 
6.671-7.574      (m, 9H, ArH) 
4.871                 (s, 1H, -NH) 
3.714                 (s, 2H, -CH2) 
3.386                 (s, 2H, (2,6) CH2 of morpholine) 
2.563                 (s, 2H (3,5) CH2 of morpholine) 
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Table-5 
           Mass Spectra 
S. No Compound Code Peak Value 
1 S3 335.80 (335) 
2 S7 368.18 (367) 
3 S9 354.32(354) 
4 S10 336.32 (336) 
Compound S3 
Compound S7 
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Compound 9 
 
Compound S10 
 
  
 
Chapter-VI 
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Chapter VI 
Docking results 
INTRODUCTION:  
IN-SILICO DRUG DESIGN 
       Drug discovery and development is an essential, intense, 
lengthy and an interdisciplinary endeavor. Drug discovery is mostly portrayed as a 
linear, consecutive process that starts with target and lead discovery, followed by lead 
optimization and pre-clinical in vitro and in vivo studies to determine if such 
compounds satisfy a number of pre-set criteria for initiating clinical development. 
  
 Traditionally drugs were discovered by synthesizing 
compounds in a time consuming multi-step processes against battery in-vivo 
biological screens and further investigating the promising candidates for the 
pharmacokinetic properties, metabolism and potential toxicity. Such a development 
processes has resulted in high attrition rates with failures attributed to poor 
pharmacokinetics (39%), lack of efficacy (30%), animal toxicity (11%), adverse 
effects in humans (10%) and various commercial and miscellaneous factors. Today, 
the processing of drug discovery has been revolutionized with the advent of 
genomics, proteomics, bioinformatics and efficient technologies like, combinatorial 
chemistry, high throughput screening (HTS), virtual screening, de novo design in 
vitro, in silico ADMET screening and structure- based drug design.Computer aided 
drug design is an interdisciplinary of bioinformatics, medicine and biophysics. 
Bioinformatics and computational methods recently were used to design new drug 
candidates that could potentially bind with target proteins, thus producing drug 
                                                                                                                   Chapter VI                              
Dept. of Pharmaceutical Chemistry,Madurai Medical College                       Page 79 
 
molecules for many disease. They also promise to speedup drug research by 
predicting potential effectiveness of designed compounds prior to experimental 
studies and preclinical trials. 
    In-silico methods can help in identifying the drug targets via bioinformatics 
tools. They can also be used to analyze the target structure for possible binding/ active 
sites, generate candidate molecules, check for their drug likeness, dock these 
molecules with the target, rank them according to their biding affinities, further 
optimize the molecules to improve binding characteristics. The use of computers and 
computational methods permeates all aspects of drug discovery today which is 
essential core of structure-based drug design. The use of in-silico drug design 
techniques increases the chance of success in many stages of the drug discovery 
process, from the identification of novel targets and elucidation of their function to the 
discovery and development of lead compounds with desired properties. 
Computational tools provide the advantage of delivering the new drug candidates 
more quickly and at lower cost. 
 
RATIONAL DRUG DESIGN 
 In-silico techniques save great amounts of time and money in R&D 
projects. A good modeling support is often what makes the difference between a 
successful drug design project and one that fails. With a strong background in the 
fields of molecular modeling, molecular biology and computational chemistry, we are 
able to offer full in-silico support for projects of drug design, protein engineering and 
intermolecular recognition. The possibility of developing software to tailor the in-
silico approach to different problems is what makes us unique. 
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TECHNIQUES 
• Molecular Docking and Virtual Screening: Docking studies are 
computational techniques for the exploration of the possible binding modes of 
a substrate to a given receptor, enzyme or other binding site. Docking is the 
process by which two molecules fit together in 3D space. Docking studies may 
help to increase ligand specificity; and also better therapeutic index can be 
achieved if the drug produces undesirable side effects due to its binding with 
another site, the affinity for that competing site can be diminished. Different 
types of docking include- flexible protein-ligand docking, flexible protein-
protein docking and hydrophobic docking. Docking may play an important 
role in the QSAR studies and homology modeling very useful in structure 
based drug design. Various docking programs are available DOCK, FLOG, 
ADAM, and UGIN.  
•  Molecular Dynamics: The prediction of the evolution of molecular 
systems over time, the study of protein conformation, protein-protein 
interactions, the simulation of biological membranes.  
• Quantum Mechanics: The study of chemical reactions, the effects of 
substitutions on electronic properties and reactivity of molecules.  
• QSAR: Quantitative structure-activity relationship. The ability of 
predicting biological properties of molecules without even the need of 
knowing their target.  
• Homology Modelling: Predicting the structures of proteins that has 
not been yet crystallized. 
 
                                                                                                                   Chapter VI                              
Dept. of Pharmaceutical Chemistry,Madurai Medical College                       Page 81 
 
DOCKING STUDIES: 
 The ability to propose reasonable binding modes of a designed 
structure to a known receptor site called docking studies, which is crucial to the 
success of structure based design. One approach is to dock or position ligand or 
receptor molecules together in many different possible ways and then scores each 
orientation according to an evaluation function of some kind. These studies can 
predict binding confirmations and affinities of millions of molecules without the need 
of a single synthetic step. These rational drug design methods accelerate the process 
by speeding up the discovery of new chemical substances that may become a new 
drug. 
DRUG-LIKENESS AND LEAD-LIKENESS 
  Christopher A. Lipinski defined the Drug likeness as the compounds those 
have sufficiently acceptable absorption, distribution, metabolism and elimination 
properties to get successful entry in to human Phase 1 clinical trials. For the drug 
development, drug properties are important prominent component. A chemically 
synthesized compound library can contain many non-drug-like compounds. 
Therefore, recent technologies helped to develop recognized drug-like compounds 
from a diverse compound library. These drug-like measuring and filtering 
technologies have partly solved the screening problems. However, they have not been 
good enough to completely solve these problems. It has been observed that many 
drug-like compounds, which should be potential candidates; do not come up as hits 
when they are screened against biological targets. Drug-likeness is the descriptors of 
all important pharmacological properties such as potency, selectivity toward receptor, 
absorption, distribution, metabolism and toxicity. In the past, these parameters were 
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optimized sequentially. Now, it is mandatory that these parameters should be 
optimized simultaneously. Properties that have been associated with oral drug-
likeness include:  
 
• Oral bioavailability 
• Appropriate toxicity to pass phase I clinical trials. 
• Aqueous solubility 
• Synthetics accessibility 
• Pharmacokinetic viability  
• Blood-brain barrier permeability. 
Lipophilicity is a key property for pharmacological activity in drug discovery 
and used to estimate the permeability of a drug molecule in the cell membrane. It is 
measured as logP value that distribution coefficient of compounds between n-octanol 
and water. 
     When logP value is very low or very high, the permeability of 
drug components get dropped due to the inability of weakly lipophilic compounds to 
penetrate the lipid portion of the membrane and the excessive partitioning of strongly 
lipophilic compounds into the lipid portion of the membrane and their subsequent 
inability to pass through the aqueous portion of the membrane. 
 Lipinski's rule helps to predict the poor absorption and permeability of 
potential drug candidates. It will occur if,  
• A molecular weight less than 500.  
• An octanol-water partition coefficient log P of less than 5. 
• Molar refractivity not more than 150 
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• Not more than 5 hydrogen bond donors (nitrogen or oxygen 
atoms with one or more hydrogen atoms) 
• Not more than 10 hydrogen bond acceptors (nitrogen or oxygen 
atoms). 
TOOLS AND MATERIALS USED 
 Auto Dock is an automated docking tool. It is designed to predict how small 
molecules, such as substrates, bind to a receptor of known 3D structures. Auto Dock 
actually consists of two main programs: one performs the docking of the ligand to a 
set of grids describing the target protein; and the other Auto Grid pre-calculates these 
grids. In addition to using them for docking, the atomic affinity grids can be 
visualized. A graphical user interface called Auto Dock Tools or ADT was utilized to 
generate grids, calculate dock score and evaluate the conformers. 
 
Accelrays Discovery Studio: 
 Accelrays Discovery Studio is a molecular graphics program intended for the 
structural visualization of proteins, nucleic acids and small biomolecules. The 
program reads in molecular coordinate files and interactively displays the molecule on 
the screen in variety of representations and color schemes. 
 
Computed atlas of surface topography of proteins (CASTp):  
 Binding sites and active sites of proteins and DNAs are often associated with 
structural pockets and cavities. castP server uses the weighted Delaunay triangulation 
and the alpha complex for shape measurements. It provides identification and 
measurements of surface accessible pockets as well as interior inaccessible cavities, 
for proteins and other molecules. It measures analytically the area and volume of each 
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pocket and cavity, both in solvent accessible surface (SA, Richards' surface) and 
molecular surface (MS, Connolly's surface). It also measures the number of mouth 
openings, area of the openings, and circumference of mouth lips, in both SA and MS 
surfaces for each pocket. 
Selection of target: 
Target for anti-tumor  drugs: 
 This work deals with synthesis of new inhibitors of cyclin/CDK 
complexes.Also, these compounds are potent inhibitors of human cellular 
proliferation. They are useful in treating a disorder mediated by elevated levels of cell 
proliferation in a mammal compared to a healthy one by administering an effective 
dose. In the treatment of proliferative diseases the interruption of the cell cycle is one 
approach. 
The phases of the cell cycle are driven by cyclin-dependent kinases. Upon 
complexation with its activating proteins, cyclin E or cyclin A, cycline-dependent 
kinase2 (CDK2) modulates the activity of many cellular substrates via 
phosphorylation on Ser and/or Thr residues. In complex with cyclin E, cycline-
dependent kinase2 (CDK2) plays a paramount role during the G1/S transition of the 
cell cycle while in complex with cyclin A, it facilitates the progression of the S phase 
of the cell cycle. Recent evidence also suggests that CDK2 may have a crucial role in 
the G2 phase of the cell cycle. The importance of cycline-dependent kinase2 (CDK2) 
for cell cycle progression has led to an active pursuit of small molecule inhibitors of 
this enzyme as a possible treatment against cancer and other hyper-proliferative 
disorders. Our current investigation was based on; first, using a structure-guided 
strategy based on cycline-dependent kinase2 (CDK2) was as appropriate means to 
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generate CDK2 inhibitors that might prove useful for the therapy of proliferative 
disorders. 
Moreover, several cores have been reported as potent CDK inhibitors 
including purines, pyrimidine and quinazolines.  
 
Targets for Non-steroidal anti-inflammatory drugs (NSAIDs): 
 Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most 
widely used therapeutics, primarily for the treatment of inflammation, especially 
arthritis. The pharmacological activity of NSAIDs is related to the suppression of 
prostaglandin biosynthesis from arachidonic acid by inhibiting the enzyme 
prostaglandin endoperoxidase, popularly known as cyclo-oxygenase (COX). It was 
discovered that COX exists in two isoforms, COX-1 and COX-2, which are regulated 
and expressed diﬀerently. COX-1 provides cytoprotection in the gastrointestinal tract 
(GIT), whereas inducible COX-2 selectively mediates inﬂammatory signals.  Since 
most of the currently available NSAIDs in the market show greater selectivity for 
COX-1 than COX-2, chronic use of NSAIDs may elicit appreciable GI irritation, 
bleeding and ulceration 
Materials and Methods 
 The structures of human cycline-dependent kinase2 (CDK2), COX-1 
and COX-2 receptors were retrieved from Protein Data Bank (PDB). All these 
molecules as well as the bound ligand of the protein were docked by using the 
software Auto Dock and the score values are predicted. The protein ligand 
interactions were also studied. All molecules were drawn using ChemDraw Ultra 8.0 
tool and energy minimized using Chem 3D Ultra 8.0 software.  
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A large number of crystal structures were available for human CDK2 in 
complex with small ligands which bind deeply within the ATP site, and which interact 
with the kinase motif, of particular interest for the purine ring system, the CDK2 
complex (PDB code: 1H0V), COX-2 (PDB code: 1cx2) and COX-1 (PDB code : 
1eqx)  is available from the PDB. 
Docking Studies using AutoDock: 
AUTODOCK: 
 Automated docking was used to locate the appropriate binding orientations 
and conformations of various inhibitors into the receptor binding pockets. To perform 
the task, the powerful genetic algorithm method implemented in the program 
AutoDock 4.0.1 was employed. Before docking the screened ligands in to the protein 
active site, the protein was prepared by deleting the substrate cofactor as well as the 
crystallographically observed water molecules and then protein was defined for 
generating the grid. Grid maps were generated by AutoGrid program. Each grid was 
centered at the crystal structure of the corresponding receptors. The grid dimensions 
were 60 A˚ X 60 A˚ X 60 A˚ with points separated by 0.375A˚. For all ligands, 
random starting positions, random orientations and torsions were used. During 
docking, grid parameters were specified for x, y and z axes as 38.808, 30.946 and 
42.249 respectively. 
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 Selection of active sites in the receptor using CASTp Software: 
 
Fig. No 1 Active sites of COX-1 
 
 
Fig. No 2 Active sites of COX-2 
 
Fig. No 3 Active sites of 1 H0V 
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Binding mode of compound  in the active site of 1- HOV  along with 
interacting amino acids 
Compound S1 
 
Compound S2 
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Compound S3 
 
Compound S4 
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Compound S5 
 
Compound S6 
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Compound S7 
 
Compound S8 
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Compound S9 
 
Compound S10 
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Binding mode of compound  in the active site of  
COX-2 along with interacting amino acids 
Compound S9 
 
Compound S3 
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Compound S10 
 
Compound S6 
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Compound S4 
 
Compound S8 
 
 
                                                                                                                   Chapter VI                              
Dept. of Pharmaceutical Chemistry,Madurai Medical College                       Page 96 
 
Binding mode of compound  in the active site of  
COX-1  along with interacting amino acids 
Compound S9 
 
Compound S3 
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Compound S6 
Compound S4 
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Compound S8 
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Table: 6, DOCKING STUDIES FOR ANTI-TUMOR ACTIVITY 
 
 
 
 
 
 
 
COMP
. 
∆G INHIBITION 
CONSTANT 
NO. OF  
H-BONDS 
INTERACTING 
AMINOACID RESIDUES 
1(S9) -7.49 3.22 µm 3 1HOV:A:LEU83:HN 
1HOV:A:HIS120:HE2 
1HOV:A:HIS130:HE2 
2(S3) -11.39 4.51 nm 1 1HOV:A:GLU121:OE2 
3(S10) -9.53 102.81 nm 1 1HOV: A: ILE141:O 
4(S1) -9.6 92.06 nm 1 1HOV:A:ALA86:O 
5(S5) -9.37 134.55 nm 1 1HOV:A:ILE141:O 
6(S6) -7.91 1.58  µm 2 1HOV:A:HIS120:HE2 
1HOV:A:HIS130:HE2 
7(S7) -8.9 299.44 nm 1 1HOV:A:ILE141:O 
8(S4) -9.29 155.64 nm 1 1HOV:A:Glu 121:O 
9(S8) -8.92 287.82 1 1HOV:A:ALA84:O 
10(S2) -9.27 161.94 nm 1 Unknown: N 
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DOCKING STUDIES FOR ANTI-INFLAMMATORY ACTIVITY: 
Table :7 Docked scores of newly designed compounds with COX-2 and COX-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comp. Auto Dock Score 
(Kcal/mol) 
Ki (µM) No of H-bonds 
 
Interacting amino acid residues  
COX-2 COX-1 COX-2 
nM 
COX-1 
uM 
COX-2 COX-1 COX-2 COX-1 
1(S9) -7.12 -4.73 5.99 uM 341.58 1 2 1CXA;A Val 80:O 1EQX A; Glu 
11:O,  
1EQX A; Glu 
11:O,  
 
2(S3) -9.16 -7.28 194.26 4.63 1 1 1CXA;A Phe 102:O 1EQX A; Glu 
15:O,  
 
3(S10) -8.83 -5.93 339.31 44.87 1 0 1CXA;A Tyr 57:HH - 
4(S1) -10.43 -4.76 22.15  326.53 0 0 -- -- 
5(S5) -9.58 -5.53 94.32  88.92  0  - 
6(S6) -9.54 -5.12 101.85  177.96 1 1 1CXA;A Gly 58:NH 1EQX A; Ser4 
:O 
 
7(S7) -10.03 -5.88 44.86 49.29 0 0 -- - 
8(S4) -9.88 -5.52 57.68  90.05 1 1 1CXA;A Gly 58:NH 1EQX A; 
Ser4 :O 
 
9(S8) -8.95 -4.30 277.38 707.78 3 1 1CXA;A Gly 49:NH, 
1CXA;A Tyr 57:HH 
1CXA;A Trp 71:HH 
1EQX A; Ser4 
:O 
 
10(S2) -10.9 -4.30 28.53  707.58 0 0 - - 
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In-silico ADME studies: 
 
An in-silico ADME computational study of the synthesized compounds was 
performed by determination of Lipinski’s parameters. Calculations were performed 
using “Molinspiration online property calculation toolkit” and “OSIRIS property 
explorer”.  
Table 8 
 Lipinski properties of the synthesized compounds  
 
Comp Molecular 
weight 
Log 
P 
H bond 
donor 
H bond 
acceptor 
Molar 
refractivity 
Number 
of 
criteria 
met 
 
rule < 500 <5 <5 <10 40-130 At least 
3 
1(S9) 354 0.98 3 6 98.99 All 
2(S3) 335 1.60 2 5 97.69 All 
3(S10) 336 2.03 1 5 95.6 All 
4(S1) 430 5.66 1 4 128.8 4 
5(S5) 342 3.79 2 4 103.3 All 
6(S6) 386 2.46 3 5 110.14 All 
7(S7) 367 3.73 1 5 108.12 All 
8(S4) 358 3.50 3 5 104.98 All 
9(S8) 421 3.52 4 7 114.73 All 
10(S2) 366 4.33 1 4 110.32 All 
 
 
 
 
  
 
Chapter-VII 
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Chapter VII 
Pharmacological evaluation 
Anticancer activity 
Introduction 
Tumor is a mass of tissues which proliferate rapidly, spread throughout the 
body and may eventually cause death of the host. Chemotherapy is an effective 
treatment against various types of cancer either singly or in combination with surgery 
and/or radiotherapy. However, chemotherapeutic effects of most of the drugs showed 
limited efficacies due to the development of various side effects. This fostered our 
attempts to evaluate various synthetic drugs against cancer as they are less likely to 
cause serious side effects.  
Selection Grouping and Acclimatization of Laboratory Animal
  
Male Swiss albino mice (20-25 gm) were produced from animal experimental 
laboratory, and used throughout the study. They were housed in micro nylon boxes in 
a control environment (temp 25±2°C) and 12 hrs dark /light cycle with standard 
laboratory diet and water ad libitum. The study was conducted after obtaining 
institutional animal ethical committee clearance. As per the standard practice, the 
mice were segregated based on their gender and quarantined for 15 days before the 
commencement of the experiment. They were fed on healthy diet and maintained in 
hygienic environment in our animal house. 
Induction of cancer using DLA cells 
Dalton’s Lymphoma ascites (DLA) cells were supplied by Amala cancer 
research center, Trissur, Kerala, India. The cells maintained in vivo in Swiss albino 
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mice by intraperitoneally transplantation. While transforming the tumor cells to the 
grouped animal the DLA cells were aspirated from peritoneal cavity of the mice using 
saline. The cell counts were done and further dilution were made so that total cell 
should be 1 x 10
6
, this dilution was given intraperitonealy. Let the tumor grow in the 
mice for minimum seven days before starting treatments.  
Treatment Protocol    
Swiss Albino mice were divided in to nine group of six each. All the animals 
in eight groups were injected with DLA cells (1 x 10
6 
cells per mouse) 
intraperitoneally, and the remaining one group is normal control group. 
 Group 1 served as the normal control.  
 Group 2 served as the tumor control. Group 1 and 2 receives normal diet and Water.   
 Group 3 served as the positive control, was treated with injection fluorouracil at 
20mg/kg body weight, Intraperitoneally
. 
  
Group 4 Served as a treatment control group and was administered synthetic drug 
(S2) in a dose of 10mg/kg intraperitoneally.  
Group 5 Served as a treatment control group and was administered synthetic drug 
(S4) in a dose of 10mg/kg intraperitoneally. 
Group 6 Served as a treatment control group and was administered synthetic drug 
(S5) in a dose of 10mg/kg intraperitoneally. 
Group 7 Served as a treatment control group and was administered synthetic drug 
(S10) in a dose of 10mg/kg intraperitoneally. 
Group 8 Served as a treatment control group and was administered synthetic drug 
(S1) in a dose of 10mg/kg intraperitoneally. 
Group 9 Served as a treatment control group and was administered synthetic drug 
(S3) in a dose of 10mg/kg intraperitoneally. 
                                                                                                                   Chapter VII                             
Dept. of Pharmaceutical Chemistry,Madurai Medical College Page 104 
 
 
Treatment 
 In this study, drug treatment was given after the 24 hrs of inoculation, once 
daily for 14 days. 
 On day 14, after the last dose, all mice from each group were sacrificed by 
euthanasia.  Blood was withdrawn from each mouse by retro orbital puncture or 
bleeding and the following parameters were checked. 
 
1. Hematological parameters 
a. WBC count   
b. RBC count  
c. Hb content 
d. Platelet count 
e. Packed cell volume 
2.   Serum enzyme and lipid profile 
a. Total Cholesterol                    (TC) 
b. Triglycerides                          (TG) 
c. Aspartate amino Transferase  (AST) 
d. Alanine amino Transferase    (ALT) 
e. Alkaline Phosphatase             (ALP) 
     3.    Derived parameter 
f. Body weight 
g. Life span (%) 
                 h.   Cancer Cell Count 
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 EVALUATION OF CLINICAL PARAMETERS 
Cancer cell count 
The fluid (0.1ml) from the peritoneal cavity of each mouse was withdrawn by 
sterile syringe and diluted with 0.8 ml of ice cold Normal saline or sterile Phosphate 
Buffer Solution and 0.1 ml of tryphan blue (0.1 mg/ml) and total numbers of the 
living cells were counted using heamocytometer. 
                               No of cells Dilution 
   Cell count = ------------------------------------------              
                        Area × Thickness of liquid film 
      Hematological parameters 
i) WBC count 
ii) RBC count 
iii) Platelet count 
iv) Hemoglobin 
v)  Packed Cell Volume 
i) WBC count 
 The total WBC count was found to be increased in cancer control, when 
compared with normal and treated tumor-bearing mice
.
  
ii) RBC and Hb 
 RBC and Hb content decreases with tumor bearing mice when compared with 
Normal control mice. 
iii) Platelets 
 In Hodgkin lymphoma, increased in platelet count often reported in laboratory 
finding. Hence, I investigated this parameter in the study.
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iv) Packed cell volume  
           In any case of anemia the packed cell volume is decreases.  
SERUM ENZYME AND LIPID PROFILE 
The serum was analyzed for the following parameters 
(a) Aspartate amino Transferase (AST) 
(b) Alanine amino Transferase    (ALT) 
(c) Alkaline Phosphatase             (ALP) 
(d) Total Cholesterol                    (TC) 
(e) Triglyceride                            (TG) 
1. TOTAL CHOLESTEROL AND TRIGLYCERIDE (lipid profile) 
 Abnormal blood lipid profile has been associated with cancer. In Hodgkin 
lymphoma, high cholesterol level and low triglyceride level has been reported. Hence 
I investigated this parameter in the study.
  
2. LIVER ENZYMES (AST, ALT, ALP). 
 Abnormal liver function seen in patient with Hodgkin lymphoma, that these 
liver enzyme levels markedly increase in tumor bearing mice. ALP is an enzyme 
mainly derived from the liver, bones and in lesser amount from intestines, placenta, 
kidneys and leukocytes. An increase in ALP levels in the serum is frequently 
associated with the variety of disease
.
 ALP comprises a group of enzyme that 
catalyzes the phosphate esters in an alkaline environment, generating an organic 
radical and inorganic phosphate. 
 Markedly elevated serum ALP, hyperalakline-phosphatasemia, is seen 
predominantly with more specific disorders; including malignant biliary cirrhosis, 
hepatic lymphoma and sarcoidosis.
 
Hence, I investigated this parameter in this study. 
 
                                                                                                                   Chapter VII                             
Dept. of Pharmaceutical Chemistry,Madurai Medical College Page 107 
 
DERIVED PARAMETERS
 
  
1. Body weight: 
   All the mice were weighed, from the beginning to 15
th
 day of the study. 
Average increase in body weight on the 15
th
 day was determined. 
2. Percentage increase in life span (ILS)
 
 
 % ILS was calculated by the following formulae 
   Life span of treated group 
 %ILS = 100x1
groupcontrolofspanLife
grouptreatedofspanLife
−     
 All biochemical investigations were done by using COBAS MIRA 
PLUS-S Auto analyzer from Roche Switzerland. 
 Hematological test are carried out in COBAS MICROS OT 18 from 
Roche. 
 Newly added Hi-Tech instruments MAX MAT used for an auto 
analyzer for all biochemistry investigations in blood sample. 
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Table No. 9 
Effect of various synthetic drugs on Hematological parameters 
 
G1 – Normal Control, G2 – Cancer Control, G3 – Positive control, G4 – Treatment 
control (S2), G5 – Treatment control (S4), G6 – Treatment control (S5), G7 – 
Treatment control (S10), G8 – Treatment control (S1), G9 – Treatment control (S3). 
All values are expressed as mean ± SEM for 6 animals in each group. 
**a – Values are significantly different from control (G1) at P < 0.001 
*b – Values are significantly different from cancer control (G2) at P < 0.05 
**b – Values are significantly different from cancer control (G2) at P < 0.01 
 
TREAT 
-MENT 
Total WBC 
Cells /mlx10
3 
Rbc Count 
Mill/cu mm 
Hb 
Gm/dl 
PCV % 
Platelets 
Lakhs/cum
m 
G1 9.96 ±1.22 4.33±0.87 12.35 ±1.08 14.63±2.21 3.12±0.66 
G2 14.32 ±2.45
a** 
2.40±0.43
a** 
7.09  ±0.93
a** 
30.55±3.55
a** 
1.54±0.44
a** 
G3 11.26 ±1.68
b** 
4.12±0.85
b** 
11.0 ±1.42
b** 
17.40±1.33
b** 
2.63±0.68
b** 
G4 13.76±2.10
b* 
2.93±0.44
b* 
9.25±0.94
b* 
24.08±2.62
b* 
1.93±0.37
b* 
G5 12.72 ±1.90
b** 
3.06±0.62
b** 
10.25±1.20
b** 
23.07±1.28
b** 
2.12 ±0.62
b** 
G6 12.50 ±1.78
b**
 3.13±0.58
b**
 10.34±1.32
b**
 22.97±1.26
b**
 2.18 ±0.28
b**
 
G7 12.36 ±1.35
b**
 3.20±0.68
b**
 10.40±1.40
b**
 22.35±1.21
b**
 2.26 ±0.45
b**
 
G8 12.05 ±1.08
b**
 3.25±0.72
b**
 10.55±1.55
b**
 20.45±1.14
b**
 2.29 ±0.65
b**
 
G9 11.70 ±1.29
b**
 3.35±0.78
b**
 10.68±1.62
b**
 19.24±1.32
b**
 2.31 ±0.58
b**
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Table No.10 
Effect of various synthetic drugs on serum Enzymes and lipid proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G1 – Normal Control, G2 – Cancer Control, G3 – Positive control, 
G4 – Treatment control (S2), G5 – Treatment control (S4), G6 – Treatment control (S5), 
G7 – Treatment control (S10), G8 – Treatment control (S1), G9 – Treatment control (S3). 
All values are expressed as mean ± SEM for 6 animals in each group. 
**a – Values are significantly different from control (G1) at P < 0.001 
*b – Values are significantly different from cancer control (G2) at P < 0.05 
**b – Values are significantly different from cancer control (G2) at P < 0.01 
Treatment 
Cholesterol 
(mg/dl) 
TGL 
(mg /dl) 
AST 
(U/L) 
ALT 
(U/L) 
ALP 
(U/L) 
G1 99.08±3.50 120.81±2.34 36.45 ±1.17 32.27 ±1.24 125.09 ±2.18 
G2 140.86±4.54
a** 
206.14±4.63
a** 
85.0±2.69
a** 
60.18±2.55
a** 
240.18±4.26
a** 
G3 110.44±3.90
b** 
154.40±2.62
b** 
55.22 ±1.56
b** 
40.40±1.52
b** 
160.26±2.23
b** 
G4 135.39±3.53
b* 
185.83±2.27
b* 
78.67 ±2.19
b* 
56.25±1.92
b* 
230.28±2.31
b* 
G5 129.29±3.42
b** 
178.46±2.35
b** 
75.49±2.58
b** 
54.52 ±1.69
b** 
221.34±2.56
b** 
G6 125.45±2.92
b** 
172.58±2.44
b** 
74.61±2.65
b** 
51.46 ±1.54
b** 
213.21±2.36
b** 
G7 123.34±2.52
b** 
169.39±2.28
b** 
72.42±2.46
b** 
49.65 ±1.39
b** 
206.19±2.54
b** 
G8 120.26±2.48
b** 
164.65±2.39
b** 
70.57±2.62
b** 
46.39 ±1.61
b** 
194.24±2.46
b** 
G9 118.48±2.62
b** 
160.52±2.24
b** 
69.44±2.54
b** 
44.42 ±1.48
b** 
185.17±2.28
b** 
                                                                                                                   Chapter VII                             
Dept. of Pharmaceutical Chemistry,Madurai Medical College Page 110 
 
 
Table No.11 
Effect of synthetic drug on the life span, body weight and cancer cell count of 
tumor induced mice. 
Treatment 
Number of 
animals 
% ILS Life 
span 
Increase in 
Body weight 
grams 
Cancer cell 
count 
ml X 10
6
 
G1 6 >>30 days 2.12±0.44 - 
G2 6 48% 7.64±0.95
a**
 2.72±0.33
a**
 
G3 6 92% 3.73±0.52
b**
 1.25±0.24
b**
 
G4 6 66% 6.40±0.82
b*
 2.22±0.40
b*
 
G5 6 68% 6.58±0.59
b**
 2.09±0.39
b**
 
G6 6 69% 6.25±0.64
b**
 1.94±0.41
b**
 
G7 6 70% 5.94±0.45
b**
 1.82±0.26
b**
 
G8 6 71% 5.76±0.38
b**
 1.73±0.34
b**
 
G9 6 74% 5.58±0.46
b**
 1.66±0.28
b**
 
 
G1 – Normal Control, G2 – Cancer Control, G3 – Positive control, G4 – Treatment 
control (S2), G5 – Treatment control (S4), G6 – Treatment control (S5), G7 – 
Treatment control (S10), G8 – Treatment control (S1), G9 – Treatment control (S3). 
All values are expressed as mean ± SEM for 6 animals in each group. 
**a – Values are significantly different from control (G1) at P < 0.001 
*b – Values are significantly different from cancer control (G2) at P < 0.05 
**b – Values are significantly different from cancer control (G2) at P < 0.01 
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HISTOPATHOLOGICAL RESULTS 
Figure No.4–NORMAL CONTROL  
                                  
SECTION SHOW STRUCTURE OF LIVER WITH SHEETS OF 
HEPATOCYTES SEPARATED BY SINUSOIDS CARTIAL VEIN & PORTAL 
TRACT APPEAR NORMAL 
Figure No.5–TUMOR CONTROL 
 
 
SECTION SHOWS STRUCTURE OF LIVER presented hepatic congestion at 
sinusoids and the portal vessel, pericentre globular micro-steatosis, Kuffe cell 
proliferation, hepatocyte diffuse necrosis and mononuclear infiltrate 
Figure No.6–STANDARD CONTROL (5-FLUORO URACIL) 
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SECTION SHOW STRUCTURE OF LIVER presented   mild hepatic congestion 
at sinusoids and the portal vessel, pericentre globular micro-steatosis, No Kuffe cell 
proliferation, mild hepatocyte diffuse necrosis and mononuclear infiltrate. 
Figure No.7–TREATMENT CONTROL (SYNTHETIC DRUG-S2) 
 
SECTION SHOW STRUCTURE OF LIVER presented moderate hepatic 
congestion at sinusoids and the portal vessel, pericentre globular micro-steatosis, less 
Kuffe cell proliferation, mild hepatocyte diffuse necrosis and mononuclear infiltrate 
 
 
Figure No.8–TREATMENT CONTROL (SYNTHETIC DRUG-S4) 
 
SECTION SHOW STRUCTURE OF LIVER presented moderate hepatic 
congestion at sinusoids and the portal vessel, pericentre globular micro-steatosis, less 
Kuffe cell proliferation, mild hepatocyte diffuse necrosis and mononuclear infiltrate. 
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Figure No.9–TREATMENT CONTROL (SYNTHETIC DRUG-S5) 
 
 
SECTION SHOW STRUCTURE OF LIVER presented   moderate  hepatic 
congestion at sinusoids and the portal vessel, pericentre globular micro-steatosis, No 
Kuffe cell proliferation, mild hepatocyte diffuse necrosis and mononuclear infiltrate. 
Figure No.10–TREATMENT CONTROL (SYNTHETIC DRUG-S10) 
 
SECTION SHOW STRUCTURE OF LIVER presented  moderate hepatic 
congestion at sinusoids and the portal vessel, pericentre globular micro-steatosis, No 
Kuffe cell proliferation, mild hepatocyte diffuse necrosis and mononuclear infiltrate. 
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Figure No.11–TREATMENT CONTROL (SYNTHETIC DRUG-S1) 
 
 
SECTION SHOW STRUCTURE OF LIVER presented   moderate  hepatic 
congestion at sinusoids and the portal vessel, pericentre globular micro-steatosis, No 
Kuffe cell proliferation, mild hepatocyte diffuse necrosis and mononuclear infiltrate. 
Figure No.12–TREATMENT CONTROL (SYNTHETIC DRUG-S3) 
 
SECTION SHOW STRUCTURE OF LIVER presented   moderate   hepatic 
congestion at sinusoids and the portal vessel, pericentre globular micro-steatosis, No 
Kuffe cell proliferation, mild hepatocyte diffuse necrosis and mononuclear infiltrate. 
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Figure-13 
 
 
 
 
Figure-14 
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Figure-15 
 
Figure-16 
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Anti-inflammatory activity 
 The anti-inflammatory activities of synthetic drugs at a dose of 10 mg/kg 
doses were evaluated using carrageenan-induced paw edema method. The 
inflammation was readily produced in the form of edema with the help of irritant such 
as carrageenan. Carrageenan is a sulphated polysaccharide obtained from sea weed 
(Rhodophyceae) and when injected cause the release of prostaglandins by the way it 
produces inflammation and edema. 
REQUIREMENTS: 
Animal                               : Albino rat (180-200 g) 
Drugs and chemicals          : Carrageenan (1%w/v), Diclofenac sodium (standard), 
                                             Carboxy methyl cellulose (1%w/v), 
Digital plethysmo meter    :  U G O Basile (Italy) 
Test compounds                :   Synthetic drugs such as S2, S1, S7, S4, S5, and S6. 
 
METHOD: 
 Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al.
 
The animals were divided into 8 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with Synthetic drugs such as S2, S1, S7, 
S4, S5, and S6. test Compounds dissolved with 0.5 ml DMSO administered  through 
orally 30 min before the carrageenan treatment. The paw volumes of the test 
compounds, standard and control groups were measured at 60,240,360 minutes of 
carrageenan treatment with the help of Digital plethysmometer (Ugo basile, Italy). 
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Mean increase in paw volume was measured and the percentage of inhibition was 
calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
TABLE No.12 
ANTI-INFLAMMATORY ACTIVITY OF SYNTHETIC DRUGS 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 
10ml/kg orally 5.86±0.96 - 
Group II 
   Std 
10mg/kg 
I.P.Diclofenac 
sodium 
1.70±0.40 70.98%*a 
Group III 
   (S6) 
10mg/kg.i.p. 2.96±0.52 49.48%*a 
Group IV 
   (S5) 
10mg/kg.i.p.  2.66±0.50 54.60%*a 
Group V 
   (S4) 
10mg/kg.i.p.  2.52±0.48 56.99%*a 
Group VI 
   (S7) 
10mg/kg.i.p.  2.46±0.42 57.04%*a 
Group VII 
   (S1) 
10mg/kg.i.p.  2.16±0.40 63.13%*a 
Group VIII 
   (S2) 
10mg/kg.i.p.  2.05±0.36 65.01%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
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Figure: 17 
  
 
 
 
  
 
Chapter-VIII 
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Chapter VIII 
Results and Discussion 
Docking studies for anti-tumor activity:  
 
 The docking results suggested that; first, the piperazinyl group (compound S3) 
will increase the hydrophobic binding interaction with the deep hydrophobic pocket 
created by Glu 121.Second, the hydrogen bonding interactions have been found, 
between the crucial features of compounds S10,S1,S5,S4 and S2 with the high 
docking scores and N–H group of ILE 141, N–H of ALA86 and Glu 121. All dock 
runs were conducted using Auto dock software. The 3D structure of the enzyme was 
used to detail intermolecular interactions between the ligand and the target protein. 
The prepared protein was used in the determination of the important amino acids in 
the predicted binding pocket.  
 
Conclusion of molecular modeling the above molecular docking study provides useful 
information for understanding the structural features of CDK2 inhibitors binding 
mode of the newly constructed CDK2 inhibitors. 
 
Docking studies for anti-inflammatory activity:  
 
 The binding affinities of synthesized compounds into the 3D structure of the 
catalytic site of COX-2 enzyme and COX-1 enzyme were determined by performing 
docking studies using auto dock software. Lamarckian genetic algorithm method, 
implemented in the program autodock 4.0.1, was employed. Binding affinity was 
evaluated by the binding free energies (∆ G, Kcal/mol), inhibition constant (Ki) and 
Hydrogen bonding (table-7). Theoretically maximum compounds showed very good 
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binding energy and docking energy ranging from -7.12 kJmol/1 to -10.43 kJmol/1 
with COX-2.  
 All synthesized compounds display improved binding energies.The molecular 
docking studies revealed that the majority of the compounds docked in to the active 
sites of the receptors and exhibited H-bonding via O or –NH group. Interestingly, 
these compounds were having less binding energy value towards COX-1 receptor 
which shows that these compounds have more affinity towards COX-2 receptor. 
These observations together with experimental results provide a good explanation for 
the potent and selective inhibitory activity of S2,S1,S7,S4,S5 and S6.  
 In vivo absorption of the new synthesized derivatives was tentatively assessed 
by means of theoretical calculations following Lipinski’s rule of five, which 
establishes that the absorption or permeation of an orally administered compounds. 
Compounds violating more than one of these rules may present bioavailability 
problems. Our results (Table 8) revealed that the quinazoline derivatives presented 
lipophilicity less than 5, with values between 0.98 and 4.33 except compound S1 
(5.66). The molecular weight of all the synthesized compounds were less than 500 
(335 > MW < 430). All derivatives have number of hydrogen bond acceptors (n-ON = 
4-7) and donors (n-OHNH = 1-4) in agreement with Lipinski’s rule. In summary, in 
silico study pointed the quinazoline derivatives synthesized in our work as potential 
candidates for new anti-inflammatory and anti-tumor agents and it was found that all 
the ligand molecules satisfied the rule for potent inhibitors 
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Synthetic Methodology: 
The titled compounds were synthesized in a 3 step process; 
• The first step in which Anthranilic acid undergoes cyclization by the treatment 
with Benzoyl chloride to yield 2-phenyl 3,4-dihydro benzoxazine 4-one. 
• The advantage is that it is an useful intermediate to afford 3-amino-2-phenyl 
quinazolin-(3H)-4one on condensation with hydrazine hydrate. 
• The presence of active hydrogen in N-3 position facilates the Mannich 
reaction to take place with several amines to yield 3-substituted amino-2-
phenyl quinazolin-(3H)-4-one derivatives. 
Characterization: 
• The melting points were found in an open end capillary tube method by 
electrically heating melting point apparatus and are uncorrected. 
• The purity of the compounds were analyzed by Thin Layer Chromatography 
using silica gel (0.5 mm thickness) as stationary phase, employing. 
Methanol : Chloroform : Water (9:1:1) as mobile phase, spots were visualized 
using Iodine vapours. 
The Rf value of the synthesized compounds were calculated 
The characterization of the titled compounds including infrared and Nuclear magnetic 
resonance spectral datas & mass spectral datas were in correlation with the expected 
structure. 
Anti-tumor activity  
Effect on Tumor Growth  
 In the DLA tumor control group, the average life span of animal was found to 
be 48% where as synthetic drug such as S2, S4, S5, S10, S1 and S3 at dose of 
10mg/kg body weight increase the life span to 66%, 68%, 69%, 70%, 71%, and 72% 
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respectively. These values were significant. However the average life span of 5- FU 
treatment was found to be 92%, indicating its potent antitumor nature.  
  It was also supported by the significant reduction in packed cell volume and 
 viable Tumor cell count in  various synthetic compounds at dose of 10 mg/kg 
treatment when compared to the DLA tumor control. (Table No .11).   
Effect on Hematological Parameters 
 As shown in (Table No.9) RBC, Hgb, Platelets were decreased and WBC 
count was significantly increased in the DLA control group compared to the normal 
control group. Treatment with various synthetic compounds such S2, S4, S5, S10, S1 
and S3 as  at dose of 10mg/kg body weight significantly increases the Hgb content, 
RBC, Platelets and significantly decreased the WBC count to about normal level. All 
these results suggest the anticancer nature of the synthetic drugs. However, the 
standard 5-FU at the dose of 20 mg/kg body weight produced better result in all these 
parameters. 
Effect on Biochemical Parameters 
 The inoculation of DLA cells caused significantly increase in the level of 
Total Cholesterol, Aspartate amino Transferase, Alanine amino Transferase, Alkaline 
Phosphatase in the tumor control animals(G2), when compared to the normal group. 
The treatment with various synthetic compounds such as at dose of 10mg/kg body S2, 
S4, S5, S10, S1 and S3 weight reversed these changes towards the normal level. 
(Table No. 10) All the value was found to be significant. The treatment with standard 
5- FU also gave similar results. 
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                In DLA tumor bearing, a regular rapid increase in Ascitic tumor volume 
was observed. Ascitic fluid is the direct nutritional source for tumor cells and a rapid 
increase in Ascitic fluid with tumor growth would be a means to meet the nutritional 
requirement of tumor cells. Treatment with various synthetic compounds such as at 
dose of 10mg/kg body weight S2, S4, S5, S10, S1 and S3  inhibited the tumor 
volume, viable tumor cell count and increased the life span of the tumor bearing mice. 
The reliable criteria for judging the value of any anticancer drug are the prolongation 
of the lifespan of animals. It may be concluded that various synthetic compounds such 
as S2, S4, S5, S10, S1 and S3 by decreasing the nutritional fluid volume and arresting 
the tumor growth increases the life span of DLA bearing mice. Thus various synthetic 
compounds such as S2, S4, S5, S10, S1 and S3 have antitumor activity against DLA 
bearing mice. 
             Usually, in cancer chemotherapy the major problems that are being 
encountered are of myelo suppression and anemia. The anemia encountered in tumor 
bearing mice is mainly due to reduction in RBC or hemoglobin percentage and this 
may occur either due to iron deficiency or due to hemolytic or myelopathic 
conditions. Treatment with various synthetic compounds such as S2, S4, S5, S10, S1 
and S3 brought back the hemoglobin (Hb) content, RBC and WBC count more or less 
to normal levels significantly. This clearly indicates that various synthetic compounds 
such as S2, S4, S5, S10, S1 and S3 possess protective action on the haemopoietic 
system. 
           It was reported that the presence of tumor in the human body or in the 
experimental animals is known to affect may function of the liver. The significantly 
elevated level of total cholesterol, TG, AST, ALT, ALP in serum of tumor inoculated 
animal indicated liver damage and loss of functional integrity of cell membrane. The 
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significant reversal of these changes towards the normal by various synthetic drugs 
treatments. 
            In the present study, the biochemical examination of DLA inoculated animals 
showed marked changes indicating the toxic effect of the tumor. The normalization of 
these effects observed in the serum treated with various synthetic compounds such as  
S2, S4, S5, S10, S1 and S3 supported the potent antitumor effect of the drugs. 
Anti- inflammatory activity 
 Various synthetic drugs such as S2, S1, S7, S4, S5, and S6 at a dose of 
10mg/kg were tested for their Anti- inflammatory activity by using carrageenan 
Induced rat paw edema method and the results are tabulated in table no 12.  The 
results reveals that   synthetic drugs S2, S1, S7, S4, S5, and S6   at 10mg/kg doses 
possesses significant Anti- inflammatory activity when compared to control group at 
p<0.01. 
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Conclusion 
 Novel 2-phenyl 3-substituted amino quinazolin-4(3H)ones were synthesized 
by a 3 step process using Anthranilic acid and Benzoyl chloride as starting 
materials. 
 The melting points were found for the synthesized compounds and are 
uncorrected. The purity of  the synthesized compounds were analyzed by Thin 
Layer Chromatography method. 
 The structures of  the synthesized compounds has been elucidated by Infra-
red, Nuclear magnetic resonance spectroscopy & Mass spectroscopy. 
 The anti-cancer activity of the synthesized compounds (10mg/kg) were 
screened by using Dalton’s Lymphoma Ascites (DLA) cells in albino mice 
against the standard drug 5-FU (20mg/kg). 
 The results obtained showed that the attachments of piperazine, 
Dicyclohexylamine,Morpholine,aniline,4-aminophenol,Indole moieties to the 
quinazolin-4(3H)-one ring exhibited significant anti-cancer activity. 
 The anti-inflammatory activity of  the synthesized compounds (10mg/kg) were 
screened by carrageenan induced paw edema method in albino rats against the 
standard drug Diclofenac sodium (10mg/kg). 
 From the obtained results quinazolin-4(3H)-one ring having substitutions like 
Indole, Dicyclohexylamine, Benzimidazole, 4-aminophenol, aniline, PABA 
showed significant anti-inflammatory activity. 
 Future investigations can be made to study its pharmacokinetic parameters, 
potency, efficacy, drug interactions, side effects of the titled compounds in 
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order to bring out the novel quinazolin-4(3H)-one derivatives as a successful 
drug molecules. 
 Extended studies can be made to broaden the therapeutic utility of the 
synthesized compounds such as anti-microbial, anti-malarial, anti-
tuberculosis, anti-HIV, anti-parkinsonism, anti-histaminic, local anaesthetic, 
anti-hypertensive and anti-viral activities.  
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